CDERLearn Training and Education
Learning opportunities for healthcare professionals, academia, students, and consumers
Search General Courses Search Industry Courses
Upcoming Events
- Generic Drugs Forum (GDF) 2024: Regulatory Considerations to Enhance Generic Drug Access – April 10-11, 2024
- FDA Drug Topics: Electronic Submission of Safety Reports – Ready for Primetime? - April 30, 2024
- Statistical Considerations for Premarketing Risk Assessment – May 16, 2024
Summary | Audience | Media | Topic |
---|---|---|---|
The Current Status of Oral Phenylephrine as a Nasal Decongestant with Dr. Theresa Michele and Dr. Ilisa Bernstein | Health Care Professionals; Patients | Drug Regulatory Process; Drug Safety; OTC Drug Regulations | |
Medication Health Fraud and Avoiding Medication Scams with Cynthia Ng | Health Care Professionals; Patients | Drug Regulatory Process; Drug Safety | |
What does FDA regulate? | Health Care Professionals; Patients | Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; OTC Drug Regulations; Women’s Health | |
Advancing Generic Drug Development: Translating Science to Approval 2023 | Health Care Professionals | Webinars | Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs |
FDA Office of Clinical Pharmacology and International Society of Pharmacometrics (ISoP) Public Workshop: Using Modeling and Simulation to Select Dosages for Combination Therapies and New Indications | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; IND |
FDA/CDER Office of Clinical Pharmacology and International Society of Pharmacometrics (ISoP) Public Workshop: Using Modeling and Simulation to Evaluate the Effects of Intrinsic and Extrinsic Factors | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Increasing the Efficiency of Biosimilar Development Programs 2023 | Health Care Professionals; Patients | Webinars | Biosimilars; Drug Development; Drug Regulatory Process; Drug Safety |
Second Annual FDA ASCO WORKSHOP on Getting the Dosage Right | Health Care Professionals; Patients | Webinars | Cancer Drugs; Drug Development; Drug Regulatory Process; Drug Safety |
CDER Conversation: Improving Medication Adherence and Patient Experience by Researching Patient Perceptions of Generic Drug | Health Care Professionals; Patients | Case Study; | Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs |
Interchangeable Biosimilars | Health Care Professionals; Patients | Case Study; Videos | Biosimilars |
Biological Products, Biosimilars Products, and Interchangeable Biosimilar Products | Health Care Professionals; Patients | Graphic | Biosimilars; Drug Regulatory Process; Drug Development |
Biosimilar Manufacturing and Variation | Health Care Professionals; Patients | Graphic | Biosimilars; Drug Regulatory Process; Drug Development |
Biosimilar Regulatory Approval Pathway | Health Care Professionals; Patients | Graphic | Biosimilars; Drug Regulatory Process; Drug Development |
Generics and Biosimilars | Health Care Professionals; Patients | Graphic | Biosimilars; Drug Regulatory Process; Drug Development; Generic Drugs |
What is a Biosimilar? | Health Care Professionals; Patients | Graphic | Biosimilars; Drug Regulatory Process; Drug Development |
What is a Biosimilar? (Spanish) | Health Care Professionals; Patients | Graphic | Biosimilars; Drug Regulatory Process; Drug Development |
Biosimilars Basics Infographic | Health Care Professionals; Patients | Infographics | Biosimilars; Generic Drugs |
Conversations on Cancer: "What's on the Horizon: Future of Cancer Care" | Health Care Professionals; Patients; | Patients; Webinars | Cancer Drugs; Disease States |
A Step Forward in the Treatment of Opioid and Alcohol Dependence with Dr. Iilun Murphy and Dr. Marta Sokolowska | Health Care Professionals; Patients | Podcasts | CE Credits; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; Opioids |
Clinical Trial Basics | Health Care Professionals | Podcasts | Biomarkers; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; IND; Women’s Health |
Clinical Trial Basics with Dr. Robert Temple | Health Care Professionals; Patients | Podcasts | Disease States; Drug Regulatory Process; Drug Development; Drug Safety; IND; Biomarker; Women’s Health |
Conversation on Paxlovid with Dr. John Farley | Health Care Professionals; Patients | Podcasts | COVID-19; Disease States; Drug Regulatory Process; Drug Development; Drug Safety |
CURE ID, A Tool for Clinicians to Report New Uses of Existing Drugs with Heather Stone and Dr. Marco Schito | Health Care Professionals; Patients | Podcasts | CE Credits; Case Study; COVID-19; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
Drug Information Soundcast in Clinical Oncology (D.I.S.C.O) | Health Care Professionals | Podcasts | Cancer Drugs; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; MedWatch; Women’s Health |
Drug Shortages with CDR Emily Thakur | Health Care Professionals; Patients | Podcasts | CE Credits; COVID-19; Drug Development; Drug Regulatory Process; Drug Safety |
FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab) | Health Care Professionals; Patients | Podcasts | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
FDA approval of Augtyro (repotrectinib) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Epkinly (epcoritamab-bysp) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Fruzaqla (fruquintinib) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Jemperli (dostarlimab-gxly) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Keytruda (pembrolizumab) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Lynparza (Olaparib) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of OGSIVEO (nirogacestat) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Omisirge (omidubicel-onlv) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States, Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Polivy (polatuzumab vedotin-piiq) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Tibsovo (ivosidenib) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approval of Trodelvy (sacituzumab govitecan-hziy) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Women’s Health |
FDA approval of Verzenio (abemaciclib) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Women’s Health |
FDA approval of Zynyz (retifanlimab-dlwr) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approvals of Jaypirca (pirtobrutinib) and Orserdu (elacestrant) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Women’s Health |
FDA approvals of Talvey and Elrexfio | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA approvals of Tukysa (tucatinib) | Health Care Professionals; Patients | Podcasts | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
FDA Drug Safety Podcasts | Health Care Professionals | Podcasts | Drug Safety;Biosimilars; Cancer Drugs; Diabetes; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; MedWatch; Women’s Health |
FDA Health Playbook | Health Care Professionals; Patients | Podcasts | Drug Safety; OTC Drug Regulations; MedWatch; Opioids |
FDA Insight | Health Care Professionals; Patients; | Podcasts | Compounding; COVID-19; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; Opioids; Women’s Health; OTC Drug Regulations |
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds | Health Care Professionals; Patients | Podcasts | Drug Development; Drug Regulatory Process; Drug Safety; IND |
FDA takes steps to decrease barriers for overdose reversal agents with Dr. Marta Sokolowska | Health Care Professionals; Patients | Podcasts | CE Credits; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; OTC Drug Regulations |
FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use | Health Care Professionals; Patients | Podcasts | Drug Development; Drug Regulatory Process; Drug Safety; MedWatch; Opioids |
FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions | Health Care Professionals; Patients | Podcasts | Drug Regulatory Process; Drug Safety; MedWatch |
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan) | Health Care Professionals; Patients | Podcasts | Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
FDA’s Regulation of Dietary Supplements with Dr. Cara Welch | Health Care Professionals; Patients | Podcasts | CE Credits; Drug Development; Drug Regulatory Process; Drug Safety |
FDA's Overdose Prevention Framework with Dr. Marta Sokolowska | Health Care Professionals; Patients | Podcasts | Disease States; Drug Regulatory Process; Drug Development; Drug Safety; MedWatch; Opioids; Cancer Drugs |
Generics-at-a-Glance with Dr. Sarah Ibrahim | Health Care Professionals; Patients | Podcasts | Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs |
Health Equity Forum Podcast | Health Care Professionals; Patients | Podcasts | COVID-19; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Diabetes; Women’s Health |
Insights About the FDA/EMA Parallel Scientific Advice Program for Complex Generic/Hybrid Drug Products | Health Care Professionals; Patients | Podcasts | Development; Drug Regulatory Process; Drug Safety; Generic Drugs |
MedWatch, Your Report Can Make a Difference with Dr. Gerald Dal Pan | Health Care Professionals | Podcasts | Disease States; Drug Development; Drug Regulatory Process; Drug Safety;Generic Drugs;MedWatch |
Navigating the World of Online Pharmacies with CDR Lysette Deshields | Health Care Professionals; Patients | Podcasts | CE Credits; Drug Regulatory Process; Drug Safety |
OMHHE Health Equity Forum Podcast - Toward Improving Race and Ethnicity Data in Healthcare | Health Care Professionals; Patients | Podcasts | Drug Development; Drug Regulatory Process |
Q&A with FDA | Health Care Professionals | Podcasts | COVID-19; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; MedWatch |
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development | Health Care Professionals; Patients | Podcasts | Biomarker; Biosimilars; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity | Health Care Professionals | Podcasts | Diabetes; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
Using Bayesian Statistical Approaches to Advance our Ability to Evaluate Drug Products | Health Care Professionals; Patients | Podcasts | Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Why Does the FDA Exist? | Health Care Professionals; Patients | Podcasts | Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Compounding Quality Center of Excellence Annual Conference 2023 | Health Care Professionals, Patients | Podcasts, Webinars | Compounding; COVID-19; Drug Development; Drug Regulatory Process; Drug Safety |
Adverse Events Associated with Compounded Drugs from Outsourcing Facilities | Health Care Professionals | Podcasts; Webinars | Case Study; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
Biosimilars in the Real World: Perspectives for Staying Within the Scope of Care | Health Care Professionals | Podcasts; Webinars | Biosimilars; Cancer Drugs; CE Credits; Case Study; Diabetes; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; MedWatch |
Compounding Quality Center of Excellence Virtual Live Training | Health Care Professionals | Podcasts; Webinars | CE Credits; Case Study; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
Equity of Voices video series | Health Care Professionals; Patients | Podcasts; Webinars | Case Study; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; MedWatch |
Putting the Patient into Perspective: Strategies for Educating Patients about Biosimilars | Health Care Professionals | Podcasts; Webinars | Biosimilars; Cancer Drugs; CE Credits; Case Study; Diabetes; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; MedWatch; Women’s Health |
Stability and Beyond Use Dates | Health Care Professionals | Podcasts; Webinars | CE Credits; Case Study; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch; Case Study |
Biosimilars Overview for Health Care Professionals | Health Care Professionals | Podcasts; Webinars | Biosimilars; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Biosimilars Resources | Health Care Professionals | Podcasts; Webinars | Biosimilars; Case Study; Drug Regulatory Process; Drug Development |
Compounding Quality Center of Excellence On-Demand Training | Health Care Professionals | Podcasts; Webinars | CE Credits; Case Study; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
Conversations on Cancer: “Cancer Misinformation: Truth or Consequences” | Health Care Professionals; Patients | Podcasts; Webinars | Cancer Drugs; Disease States, Drug Development; Drug Regulatory Process; Drug Safety |
Minority Health and Health Equity Webinars | Health Care Professionals; Patients | Podcasts; Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Accelerating Access to Critical Therapies for ALS | Health Care Professionals; Patients | Videos | Biomarker; Disease States; Drug Development; Drug Regulatory Process |
Accelerating Rare disease Cures (ARC) Program | Health Care Professionals; Patients | Videos | Biomarker; Disease States; Drug Development; Drug Regulatory Process |
Biosimilar and Interchangeable Biologics: More Treatment Choices | Health Care Professionals; Patients | Videos | Biosimilars |
Biosimilar Medications – What Health Care Providers Need to Know | Health Care Professionals; Patients | Videos | Biosimilars; Drug Regulatory Process; Drug Development; Drug Safety |
Biosimilar Medications — What Patients Need to Know | Health Care Professionals; Patients | Videos | Biosimilars; Drug Regulatory Process; Drug Development; Drug Safety |
Biosimilars Curriculum Materials for Health Care Degree Programs | Health Care Professionals; Patients | Videos | Biosimilars; Case Study; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs |
Biosimilars Multimedia Education Materials | Health Care Professionals; Patients | Videos | Biosimilars; Drug Regulatory Process; Drug Development; Drug Safety |
Biosimilars Videos | Health Care Professionals | Videos | Drug Development; Biosimilars; Drug Regulatory Process |
FDA Drug Info Rounds | Health Care Professionals | Videos | Drug Safety; MedWatch; IND; Drug Development; Drug Regulatory Process; Prescription Drug Promotion; Disease States; Registration and Listing; Generic Drugs |
FDA Overview of Biosimilar Products | Health Care Professionals | Videos | Biosimilars;Drug Regulatory Process; Drug Development |
FDA Review and Approval Process for Biosimilar Medications | Health Care Professionals; Patients | Videos | Biosimilars; Drug Regulatory Process; Drug Development; Drug Safety |
FDA's Biomarker Qualification Program | Videos | Biomarker; Drug Development | |
GDUFA II Videos and Resources | Videos | Drug Development; Generic Drugs | |
Overview of FDA role regulating and approving drugs | Health Care Professionals; Patients | Videos | Drug Development; Drug Regulatory Process; Drug Safety; MedWatch |
Regulatory Science at CDER Videos | Videos | Drug Regulatory Process; Drug Development | |
14th Annual Sentinel Initiative Public Workshop | Health Care Professionals; Patients | Webinars | COVID-19; Disease States; Drug Regulatory Process; Drug Development; Drug Safety |
6 Tip-Offs to Rip-Offs: Don't Fall for Health Fraud Scams | Health Care Professionals; Patients | Webinars | Drug Safety |
Achieving Data Quality and Integrity in Maximum Containment Laboratories | Health Care Professionals; Patients | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Advancing the Use of Complex Innovative Designs in Clinical Trials: From Pilot to Practice | Health Care Professionals | Webinars | Case Study; Drug Development; Drug Regulatory Process; Drug Safety |
Airflow | Health Care Professionals | Webinars | CE Credits; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Application of Artificial Intelligence and Machine Learning for Precision Medicine | Health Care Professionals; Patients | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Areas of Customer Need for Outsourcing Facility Products | Health Care Professionals; Patients | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Aseptic Process Simulations (Media Fills) | Health Care Professionals | Webinars | CE Credits; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Bench to Bedside: Integrating Sex and Gender to Improve Human Health | Health Care Professionals | Webinars | CE Credits; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Women's Health |
BeSafeRx: Your Source for Online Pharmacy Information | Health Care Professionals; Patients | Webinars | Drug Safety |
Biosimilars 102: Interchangeability, Extrapolation, and Immunogenicity - A Regulatory Process Primer (medscape.org) | Health Care Professionals | Webinars | Biosimilars; CE Credits; Drug Regulatory Process; Drug Development |
Bridging Efficacy and Safety to the Obese | Health Care Professionals | Webinars | Biomarker;Cancer Drugs;Diabetes;Disease States;Drug Development;Drug Regulatory Process;Drug Safety;Generic Drugs;IND;MedWatch;Women's Health |
CDER Webinars | Health Care Professionals | Webinars | Drug Regulatory Process; Drug Development; Generic Drugs; OTC Drug Regulations; Registration and Listing; Electronic Submissions; Biosimilars; Drug Safety; MedWatch; IND; Disease States; Prescription Drug Promotion; Cancer Drugs |
Cleanroom In-person Course | Health Care Professionals | Webinars | Compounding; Drug Regulatory Process; Drug Development |
Compounding Outsourcing Facilities Annual Study | Health Care Professionals; Patients | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Compounding Quality Center of Excellence Virtual Conference | Health Care Professionals; Patients | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer, Black History Month Program: “Real Talk: Our Stories as Black Oncologists at the FDA” | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer: “Seasons of Change: Oncology Careers” | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States |
Conversations on Cancer: Bringing Innovation to People Facing Cancer | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer: Cancer Disparities in Appalachia | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer: How Biotech Built a Blockbuster Cancer Drug | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer: Living with Metastatic Breast Cancer | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer: National Black Family Cancer Awareness Week, Engaging the Generations | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Conversations on Cancer: Transforming Patient Lives by Therapeutic and Regulatory Innovations | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Division of Drug Information Webinars | Health Care Professionals | Webinars | CE Credits; Drug Regulatory Process; Drug Development; Generic Drugs; OTC Drug Regulations; Biosimilars; Drug Safety; MedWatch; IND; Disease States; Prescription Drug Promotion; Cancer Drugs |
Engaging Providers to Address Knowledge Gaps on Medication Use in Pregnancy and Lactation | Health Care Professionals | Webinars | CE Credits; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; MedWatch; Women's Health |
Environmental Monitoring In-person Course | Health Care Professionals | Webinars | CE Credits; Compounding; Drug Regulatory Process; Drug Development |
FDA 101: An Overview of FDA's Regulatory Review and Research Activities | Health Care Professionals; Patients | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; IND; OTC Drug Regulations; Women’s Health |
FDA Grand Rounds | Health Care Professionals; Patients | Webinars | COVID-19; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; MedWatch; Generic Drugs; OTC Drug Regulations; Biosimilars; IND; Cancer Drugs; Biomarker; Women’s Health |
FDA Rare Disease Day 2023 | Health Care Professionals; Patients | Webinars | Biomarker; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Health Fraud Scams | Health Care Professionals; Patients | Webinars | Drug Safety |
Highlights in Oncofertility: Trends in an Emerging Field for Cancer Survivors | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Women’s Health |
Increasing the Efficiency of Biosimilar Development Programs | Health Care Professionals | Webinars | Biosimilars;Drug Regulatory Process; Drug Development |
Insanitary Conditions and Sterility Assurance | Health Care Professionals | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Investigations and Corrective and Preventive Actions (CAPA) | Health Care Professionals | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Investigations and Corrective and Preventive Actions (CAPA) Virtual Course | Health Care Professionals | Webinars | Compounding; Drug Regulatory Process; Drug Development |
Joint US FDA – Health Canada ICH Public Meeting | Health Care Professionals; Patients | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; IND |
Leveraging Real-World Data to Study Medication Use in Pregnancy and Lactation | Health Care Professionals; Patients | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; MedWatch; Women's Health |
Maximizing Benefits and Minimizing Harms from Antibiotics | Health Care Professionals; Patients | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; MedWatch |
Medical Extended Reality: Applications and Challenges | Health Care Professionals; Patients | Webinars | Disease States; Drug Regulatory Process; Drug Development; Drug Safety |
Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program | Health Care Professionals | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender | Health Care Professionals; Patients | Webinars | Cancer Drugs; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; MedWatch; Opioids; Women's Health |
Outsourcing Facility Guide | Health Care Professionals | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Personnel Gowning in Sterile Drug Production | Health Care Professionals | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Pregnancy and Lactation Medication Information for the Healthcare Provider | Health Care Professionals | Webinars | CE Credits; Women’s Health; Disease States; Drug Regulatory Process; Drug Safety |
Process Validation Virtual Course | Health Care Professionals | Webinars | CE Credits; Compounding; Drug Regulatory Process; Drug Development |
Quality Management Systems Virtual Course | Health Care Professionals | Webinars | CE Credits; Compounding; Drug Regulatory Process; Drug Development |
READDI for the next pandemic | Health Care Professionals | Webinars | Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Regulatory Framework for Human Drug Compounding | Health Care Professionals | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
State of Outsourcing Facility Sector and Possibilities for the Future | Health Care Professionals; Patients | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Sterile Drug Compounding In-person Course | Health Care Professionals | Webinars | CE Credits; Compounding; Drug Regulatory Process; Drug Development |
Sterility Testing: Common Misconceptions | Health Care Professionals | Webinars | CE Credits; Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
Successfully Navigating the USPTO and FDA | Webinars | CE Credits; Drug Development; Drug Regulatory Process; Drug Safety; Registration and Listing | |
Supplier/Contractor Qualification and Management | Health Care Professionals | Webinars | Compounding; Disease States; Drug Development; Drug Regulatory Process; Drug Safety |
The History of FDA | Health Care Professionals | Webinars | Drug Development; Drug Regulatory Process; Drug Safety |
Topics in Public Health | Health Care Professionals; Patients | Webinars | Biomarker; Biosimilars; Cancer Drugs; CE Credits; Case Study; Compounding; COVID-19; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; IND; MedWatch; Opioids; OTC Drug Regulations; Women's Health |
Web-based Enduring Materials | Health Care Professionals | Webinars | Biomarker; Biosimilars; Cancer Drugs; CE Credits; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; IND; MedWatch; Opioids; OTC Drug Regulations |
Advancing Regulatory Science at FDA | Health Care Professionals; Patients | Biomarker; Disease States; Drug Development; Drug Regulatory Process | |
Are you on a biologic medication? What you need to know about biosimilar treatment options | Health Care Professionals; Patients | Biosimilars; Disease States; Drug Development; Drug Regulatory Process; Drug Safety | |
Biosimilar Basics | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Biosimilar Basics for Patients | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Biosimilares: Lo que los pacientes con diabetes deben saber | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Biosimilares: Lo que los pacientes deben saber | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Biosimilars 101: A Primer for Your Practice | Health Care Professionals | Biosimilars; Cancer Drugs; CE Credits; Case Study; Diabetes; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; MedWatch; Women’s Health | |
Biosimilars Level 1: Foundational Concepts | Health Care Professionals | Biosimilars; Case Study Drug Regulatory Process; Drug Development | |
Biosimilars Level 2: Regulatory and Scientific Concepts | Health Care Professionals | Biosimilars; Case Study Drug Regulatory Process; Drug Development | |
Biosimilars Patient Materials | Patients | Biosimilars; Drug Regulatory Process; Drug Development; Disease States; Drug Safety | |
Biosimilars: Are they the same quality? | Health Care Professionals; Patients | Biosimilars; Disease States; Drug Regulatory Process; Drug Development; Drug Safety | |
Biosimilars: What Patients Need to Know | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Biosimilars: What Patients With Diabetes Need To Know | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Biosimillars Health Care Provider Materials | Health Care Professionals | Biosimilars; Drug Regulatory Process; Drug Development; Disease States; Drug Safety | |
Conceptos básicos sobre los biosimilares | Patients | Biosimilars; Diabetes; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
C-Path Scientific Breakthrough Summit 2023 | Health Care Professionals | Drug Development; Drug Regulatory Process; Drug Safety | |
Drug Approval Case Studies | Health Care Professionals; Patients | Case Study; Diabetes; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs; IND | |
Expanded Access with Dr. Jacqueline Corrigan-Curay | Health Care Professionals; Patients | CE Credits; Disease States; Drug Development; Drug Regulatory Process; Drug Safety; IND | |
FDA MedWatch and Patient Safety | Health Care Professionals | MedWatch; Drug Safety | |
FDA's Role in Public Health: Drug Efficacy, Safety, Quality, and Beyond | Health Care Professionals | Drug Regulatory Process | |
FDA's Work to Combat the COVID-19 Pandemic | Health Care Professionals; Patients | COVID-19; Disease States; Drug Development; Drug Regulatory Process; Drug Safety | |
Health Fraud Product Database | Health Care Professionals; Patients | Drug Safety | |
How to Use the Consumer Complaint System and MedWatch | Health Care Professionals; Patients | Drug Safety; MedWatch | |
Incorporating Biosimilars Into the Management of Patients With Immunological Conditions | Health Care Professionals | Biosimilars; Cancer Drugs; CE Credits; Case Study; Diabetes; Disease States; Drug Regulatory Process; Drug Development; Drug Safety; Generic Drugs; MedWatch; Women’s Health | |
Interchangeable Biological Products | Health Care Professionals; Patients | Biosimilars | |
Leveraging Health Literacy and Patient Preferences to Reduce Hypoglycemia Events in Patients with Type 2 Diabetes | Health Care Professionals | Diabetes; Disease States | |
Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors | Health Care Professionals; Patients | Drug Regulatory Process; Drug Safety; MedWatch; Opioids | |
Reporting Unlawful Sales of Medical Products on the Internet | Health Care Professionals; Patients | Drug Safety | |
Risk Evaluation and Mitigation Strategies (REMS) Program Part 1 | Health Care Professionals; Patients | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Risk Evaluation and Mitigation Strategies (REMS) Program Part 2 | Health Care Professionals; Patients | Disease States; Drug Development; Drug Regulatory Process; Drug Safety; Generic Drugs | |
Safe Opioid Disposal | Disease States; Drug Regulatory Process; Drug Development; Drug Safety; MedWatch; Generic Drugs; Cancer Drugs; Opioids | ||
SBIA Chronicles | Health Care Professionals | Drug Regulatory Process; Prescription Drug Promotion | |
Successes and Opportunities in Modeling and Simulation for FDA | Health Care Professionals; Patients | Biomarker; Disease States; Drug Development; Drug Regulatory Process | |
Summary Report for Biosimilars | Health Care Professionals; Patients | Biosimilars; Disease States; Drug Development; Drug Regulatory Process; Drug Safety | |
The FDA Bad Ad Program and Prescription Drug Promotion | Health Care Professionals; Patients | Prescription Drug Promotion | |
The FDA Process for Approving Generic Drugs | Health Care Professionals | Drug Regulatory Process; Drug Development; Generic Drugs | |
Overcoming Reluctance and Enhancing Biosimilar Adoption | Health Care Professionals | Biosimilars; CE Credits; Drug Regulatory Process |
Additional Resources
Sub-Topic Paragraphs
Paragraph Header
Contact Us
Paragraph Header
Contact Us
Contact Point
Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993
Toll Free
(855) 543-3784
(301) 796-3400
Hours Available
CDER Division of Drug Information
For Updates on Twitter follow
Contact Point Twitter
@FDA_Drug_Info
Your source for the latest drug information.
Know the moment it happens.